Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor

Executive Summary

Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)

You may also be interested in...



Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage

Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage

Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Merck has held a monopoly on the dipeptidyl peptidase-4 inhibitor market for type 2 diabetes since launching Januvia (sitagliptin)in 2006 - a franchise that's now approaching blockbuster status - but within the next year it could be sharing scripts with two new rivals

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel